A study to assess the safety and tolerability of AZD1152 in combination with low dose cytosine arabinoside (LDAC) in patients with acute myeloid leukaemia (AML). The first three patients to complete a 28 day cycle in the cohort, before the second three patients start treatment.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
4
Variable dose via a 7-day continuous infusion
20 mg subcutaneous injection given twice daily
Research Site
Cleveland, Ohio, United States
Research Site
Houston, Texas, United States
Research Site
Le Chesnay, France
Research Site
Villejuif, France
Safety as measured by Adverse Events, Vital Signs, ECGs, Clinical Chemistry, Haematology and Urinalysis
Time frame: Information on these will be collected from the time of informed consent is signed, throughout the study.
Assessment of the pharmacokinetics of AZD1152, its active moiety AZD1152 hQPA, and LDAC.
Time frame: During the first treatment cycle for AZD1152, pre-dose and Days 2, 3,7, 8, 9, 10, 15 and 22. For LDAC, Days 7 and 10.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.